✨ Legal and Health Notices
NEW ZEALAND GAZETTE, No. 104 — 12 OCTOBER 2017
Notice of Vesting of Property Under Section 324 of the Companies Act 1993— Stoke Finance Limited
I, William Henry David More, Senior Solicitor, acting under delegated authority from the Secretary to the Treasury, hereby give notice that on 3 October 2017 I first became aware that the Crown was vested under section 324(1) of the Companies Act 1993 (by virtue of the removal of Stoke Finance Limited from the Register of Companies on 14 October 2008) with the rights to funds held by the Bank of New Zealand.
Dated at Wellington this 3rd day of October 2017.
WILLIAM HENRY DAVID MORE, Senior Solicitor.
2017-go5240
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product:
Afluria Quad
Active Ingredients:
- Influenza virus A/Hong Kong/4801/2014 (H3N2) – like strain 15mcg
- Influenza virus A/Michigan/45/2015 (H1N1) pdm09 – like strain 15mcg
- Influenza virus B/Brisbane/60/2008 – like strain 15mcg
- Influenza virus B/Phuket/3073/2013 – like strain 15mcg
Dosage Form:
Suspension for injection
New Zealand Sponsor:
Seqirus (NZ) Limited
Manufacturer:
Seqirus Pty Limited, Parkville, Australia
Product:
Elelyso
Active Ingredient:
Taliglucerase alfa 200U
Dosage Form:
Powder for injection
New Zealand Sponsor:
Pfizer New Zealand Limited
Manufacturers:
Wasserburger Arzneimittelwerk GmbH, Wasserburg, Germany
Pharmacia & Upjohn Company, Michigan, United States of America
Dated this 6th day of October 2017.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).
2017-go5253
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
Product:
Etopophos
Active Ingredient:
Etoposide phosphate 119.3mg equivalent to etoposide 100mg
Dosage Form:
Powder for injection
New Zealand Sponsor:
Bristol-Myers Squibb (NZ) Limited
Manufacturer:
Baxter Oncology GmbH, Halle-Kunsebeck Westfalen, Germany
Product:
Etopophos
Active Ingredient:
Etoposide phosphate 579.4mg equivalent to etoposide 500mg
Dosage Form:
Powder for injection
New Zealand Sponsor:
Bristol-Myers Squibb (NZ) Limited
Manufacturer:
Baxter Oncology GmbH, Halle-Kunsebeck Westfalen, Germany
40
Next Page →
✨ LLM interpretation of page content
🏭 Notice of Vesting of Property Under Section 324 of the Companies Act 1993
🏭 Trade, Customs & Industry3 October 2017
Companies Act 1993, Vesting of Property, Stoke Finance Limited, Bank of New Zealand
- William Henry David More, Senior Solicitor
🏥 Consent to the Distribution of New Medicines
🏥 Health & Social Welfare6 October 2017
Medicines Act 1981, New Medicines, Afluria Quad, Elelyso, Influenza Vaccine, Taliglucerase alfa
- Chris James, Group Manager, Medsafe, Ministry of Health
🏥 Consent to the Distribution of New Medicines
🏥 Health & Social WelfareMedicines Act 1981, New Medicines, Etopophos, Etoposide phosphate
NZ Gazette 2017, No 104